Unlike tirzepatide, which targets two receptors (GIP + GLP-1), retatrutide activates three: GIP, GLP-1, and glucagon receptors
In the SURMOUNT-5 trial, published in the New England Journal of Medicine, patients receiving tirzepatide had a mean percent decrease in body weight of 20.2%, compared with 13.7% for those receiving semaglutide,over 72 weeks
In turn, a GLP-1RA will optimize the prandial endogenous insulin response to control PPG
[9] Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity, Global Newswire, Sept
[2] [3] Substantial clinical trial data demonstrate semaglutide's effects on liver enzymes and hepatic health
Smriti Choudhary, MD , and her team to achieve your weight-loss goals